152459-95-5 ...

152459-95-5 C29H31N7O Imatinib
152459-95-5 C29H31N7O Imatinib
152459-95-5 C29H31N7O Imatinib
152459-95-5 C29H31N7O Imatinib
152459-95-5 C29H31N7O Imatinib

152459-95-5 C29H31N7O Imatinib

Min.Order / FOB Price:Get Latest Price

10 Gram

Negotiable

  • Min.Order :10 Gram
  • Purity: 99%
  • Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

152459-95-5 C29H31N7O Imatinib 152459-95-5 C29H31N7O

Quick Details

  • Appearance:white powder
  • Application:Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib als
  • PackAge:Woven bag
  • ProductionCapacity:1|Kilogram|Day
  • Storage:Normal temperature
  • Transportation:Ocean shipping Express delivery

Superiority:

Imatinib Basic information
Product description Approved indications in Europe, the United States and other countries Precautions Application
Product Name: Imatinib
Synonyms: IMA-3;IMATINIB;IMATINIB-D3;AKOS 91378;IMATINIB 99+%;Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-;Imatinib Mesilate;4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
CAS: 152459-95-5
MF: C29H31N7O
MW: 493.6
EINECS:  
Product Categories: Molecular Targeted Antineoplastic;Pharmaceutical intermediate;Imatinib;Aromatics;Heterocycles;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals;API;GLEVEEC;Antineoplastic;Anti-cancer & immunity;Inhibitors
Mol File: 152459-95-5.mol
Imatinib Structure
 
Imatinib Chemical Properties
mp  208-210°C (dec.)
storage temp.  Refrigerator
CAS DataBase Reference 152459-95-5(CAS DataBase Reference)
 
Safety Information
MSDS Information
 
 
Imatinib Usage And Synthesis
Product description Imatinib is a kind of oral drugs used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon. CML is a kind of hematopoietic stem cell disease caused by the DNA abnormalities in the bone marrow stem cells. DNA abnormalities will produce abnormal proteins and interfere with the normal generation process of the white blood cells in the bone marrow, resulting in the sharp increase in the number of white blood cells. CML is divided into three phases including chronic phase, accelerated phase and crisis phase with the average survival period of the patients in crisis phase being only 2-3 months. 
Imatinib is also effective in treating the gastrointestinal stromal tumor with the efficiency being about 50%.
Approved indications in Europe, the United States and other countries Novartis's imatinib (imatinib, Glivec) had been approved in Switzerland for being used as first-line drug for the treatment of early-stage adult chronic myelogenous leukemia and can also be applied to patients with various types of chronic granulocytic leukemia. Switzerland is the first countries which had approved to additionally include the above two indications of this drug. 
On July 28, 2006, the European Agency for the Evaluation of Medicinal Products (EMEA) had recommended the imatinib (Gleevec) of the Novartis Company for the treatment of two new indications-dermatofibrosarcoma protuberans (DFSP) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). These final approvals of these two indications still need to wait the decision of the European Food and Drug Administration. 
In addition, Novartis has announced that the application of imatinib in treating hypereosinophilic syndrome and systemic mastocytosis is still in the approval process of FDA and EMEA. 
The drug has currently been approved in Europe, the United States and other countries for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph + CML) and gastrointestinal stromal tumors. 
The above information is edited by the Chemicalbook of Dai Xiongfeng.
Precautions When combined with Ketoconazole, itraconazole, erythromycin, clarithromycin, the Cmax of this drug can (the maximum plasma concentration after the first drug administration) be increased by an average of 26% with the AUC being increased by 40%. 
The inducers of the metabolizing enzyme of hepatic drugs such as dexamethasone, phenytoin, carbamazepine, rifampicin and barbiturates can significantly reduce blood concentration of the drug. 
When the CYP3A4 metabolized substrates such as simvastatin, cyclosporine, pimozide, etc. were used in combined with imatinib, the plasma concentration of those drugs can be increased due to its competing with the drug enzyme.
Application Imatinib can be used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon.
Chemical Properties Orange Solid
Usage Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib
Usage antineoplastic
Usage atypical antipsychotic
Usage Imatinib impurity.
 
Imatinib Preparation Products And Raw materials
 

 

Details:

Imatinib Basic information
Product description Approved indications in Europe, the United States and other countries Precautions Application
Product Name: Imatinib
Synonyms: IMA-3;IMATINIB;IMATINIB-D3;AKOS 91378;IMATINIB 99+%;Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-;Imatinib Mesilate;4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
CAS: 152459-95-5
MF: C29H31N7O
MW: 493.6
EINECS:  
Product Categories: Molecular Targeted Antineoplastic;Pharmaceutical intermediate;Imatinib;Aromatics;Heterocycles;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals;API;GLEVEEC;Antineoplastic;Anti-cancer & immunity;Inhibitors
Mol File: 152459-95-5.mol
Imatinib Structure
 
Imatinib Chemical Properties
mp  208-210°C (dec.)
storage temp.  Refrigerator
CAS DataBase Reference 152459-95-5(CAS DataBase Reference)
 
Safety Information
MSDS Information
 
 
Imatinib Usage And Synthesis
Product description Imatinib is a kind of oral drugs used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon. CML is a kind of hematopoietic stem cell disease caused by the DNA abnormalities in the bone marrow stem cells. DNA abnormalities will produce abnormal proteins and interfere with the normal generation process of the white blood cells in the bone marrow, resulting in the sharp increase in the number of white blood cells. CML is divided into three phases including chronic phase, accelerated phase and crisis phase with the average survival period of the patients in crisis phase being only 2-3 months. 
Imatinib is also effective in treating the gastrointestinal stromal tumor with the efficiency being about 50%.
Approved indications in Europe, the United States and other countries Novartis's imatinib (imatinib, Glivec) had been approved in Switzerland for being used as first-line drug for the treatment of early-stage adult chronic myelogenous leukemia and can also be applied to patients with various types of chronic granulocytic leukemia. Switzerland is the first countries which had approved to additionally include the above two indications of this drug. 
On July 28, 2006, the European Agency for the Evaluation of Medicinal Products (EMEA) had recommended the imatinib (Gleevec) of the Novartis Company for the treatment of two new indications-dermatofibrosarcoma protuberans (DFSP) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). These final approvals of these two indications still need to wait the decision of the European Food and Drug Administration. 
In addition, Novartis has announced that the application of imatinib in treating hypereosinophilic syndrome and systemic mastocytosis is still in the approval process of FDA and EMEA. 
The drug has currently been approved in Europe, the United States and other countries for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph + CML) and gastrointestinal stromal tumors. 
The above information is edited by the Chemicalbook of Dai Xiongfeng.
Precautions When combined with Ketoconazole, itraconazole, erythromycin, clarithromycin, the Cmax of this drug can (the maximum plasma concentration after the first drug administration) be increased by an average of 26% with the AUC being increased by 40%. 
The inducers of the metabolizing enzyme of hepatic drugs such as dexamethasone, phenytoin, carbamazepine, rifampicin and barbiturates can significantly reduce blood concentration of the drug. 
When the CYP3A4 metabolized substrates such as simvastatin, cyclosporine, pimozide, etc. were used in combined with imatinib, the plasma concentration of those drugs can be increased due to its competing with the drug enzyme.
Application Imatinib can be used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon.
Chemical Properties Orange Solid
Usage Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib
Usage antineoplastic
Usage atypical antipsychotic
Usage Imatinib impurity.
 
Imatinib Preparation Products And Raw materials
 
  HenNan sunlake enterprise corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion, The com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material . 
   Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs , Water treatment chemicals , Food & FEED additives and others . these products have been being well exported to europe , southeast Asia , the Middle East , Africa , South America and some other countries and areas. 
    We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you better with our high - quality products and professional team. 
     We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market. We welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate with you for a brilliant future!
 

View All
Visit Store

You Might Also Like

Related Searches

Contact Supplier

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View